- Home
- INSW vs NAMS Comparison
INSW vs NAMS Comparison
Compare INSW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSW | NAMS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INSW | NAMS |
|---|---|---|
| Price | $96.88 | $26.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $77.00 | $46.75 |
| AVG Volume (30 Days) | 496.4K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ 11.66 | N/A |
| Revenue | ★ $843,302,000.00 | $22,503,000.00 |
| Revenue This Year | $10.20 | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.25 | $23.05 |
| 52 Week High | $98.23 | $42.21 |
Technical Indicators
Market Signals| Indicator | INSW | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 33.39 |
| Support Level | $75.16 | $25.74 |
| Resistance Level | $98.23 | $37.29 |
| Average True Range (ATR) | 3.54 | 1.33 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 81.39 | 17.95 |
Price Performance
Historical ComparisonAbout INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. Its fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.